These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
817 related articles for article (PubMed ID: 28476288)
1. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Gupta A; Thompson D; Whitehouse A; Collier T; Dahlof B; Poulter N; Collins R; Sever P; Lancet; 2017 Jun; 389(10088):2473-2481. PubMed ID: 28476288 [TBL] [Abstract][Full Text] [Related]
2. Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial. Gupta A; Mackay J; Whitehouse A; Godec T; Collier T; Pocock S; Poulter N; Sever P Lancet; 2018 Sep; 392(10153):1127-1137. PubMed ID: 30158072 [TBL] [Abstract][Full Text] [Related]
3. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Sever PS; Dahlöf B; Poulter NR; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J; Drugs; 2004; 64 Suppl 2():43-60. PubMed ID: 15765890 [TBL] [Abstract][Full Text] [Related]
5. The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K. Sever PS; Chang CL; Gupta AK; Whitehouse A; Poulter NR; Eur Heart J; 2011 Oct; 32(20):2525-32. PubMed ID: 21873710 [TBL] [Abstract][Full Text] [Related]
6. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Sever PS; Dahlöf B; Poulter NR; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J; Lancet; 2003 Apr; 361(9364):1149-58. PubMed ID: 12686036 [TBL] [Abstract][Full Text] [Related]
7. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension. Sever PS; Poulter NR; Dahlof B; Wedel H; J Hypertens; 2009 May; 27(5):947-54. PubMed ID: 19318984 [TBL] [Abstract][Full Text] [Related]
8. Study protocol for statin web-based investigation of side effects (StatinWISE): a series of randomised controlled N-of-1 trials comparing atorvastatin and placebo in UK primary care. Herrett E; Williamson E; Beaumont D; Prowse D; Youssouf N; Brack K; Armitage J; Goldacre B; MacDonald T; Staa TV; Roberts I; Shakur-Still H; Smeeth L BMJ Open; 2017 Dec; 7(12):e016604. PubMed ID: 29197834 [TBL] [Abstract][Full Text] [Related]
9. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). Sever PS; Poulter NR; Dahlöf B; Wedel H; Collins R; Beevers G; Caulfield M; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J Diabetes Care; 2005 May; 28(5):1151-7. PubMed ID: 15855581 [TBL] [Abstract][Full Text] [Related]
10. Ethnic variations in lipid-lowering in response to a statin (EVIREST): a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Chapman N; Chang CL; Caulfield M; Dahlöf B; Feder G; Sever PS; Poulter NR Ethn Dis; 2011; 21(2):150-7. PubMed ID: 21749017 [TBL] [Abstract][Full Text] [Related]
11. Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis. ; Lancet Diabetes Endocrinol; 2024 May; 12(5):306-319. PubMed ID: 38554713 [TBL] [Abstract][Full Text] [Related]
12. Development and Validation of a Model to Predict Absolute Vascular Risk Reduction by Moderate-Intensity Statin Therapy in Individual Patients With Type 2 Diabetes Mellitus: The Anglo Scandinavian Cardiac Outcomes Trial, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, and Collaborative Atorvastatin Diabetes Study. Kaasenbrood L; Poulter NR; Sever PS; Colhoun HM; Livingstone SJ; Boekholdt SM; Pressel SL; Davis BR; van der Graaf Y; Visseren FL; Circ Cardiovasc Qual Outcomes; 2016 May; 9(3):213-21. PubMed ID: 27174798 [TBL] [Abstract][Full Text] [Related]
13. Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials. Herrett E; Williamson E; Brack K; Beaumont D; Perkins A; Thayne A; Shakur-Still H; Roberts I; Prowse D; Goldacre B; van Staa T; MacDonald TM; Armitage J; Wimborne J; Melrose P; Singh J; Brooks L; Moore M; Hoffman M; Smeeth L; BMJ; 2021 Feb; 372():n135. PubMed ID: 33627334 [TBL] [Abstract][Full Text] [Related]
14. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Livingstone SJ; Thomason MJ; Mackness MI; Charlton-Menys V; Fuller JH; Lancet; 2004 Aug 21-27; 364(9435):685-96. PubMed ID: 15325833 [TBL] [Abstract][Full Text] [Related]
15. High-Dose Perioperative Atorvastatin and Acute Kidney Injury Following Cardiac Surgery: A Randomized Clinical Trial. Billings FT; Hendricks PA; Schildcrout JS; Shi Y; Petracek MR; Byrne JG; Brown NJ JAMA; 2016 Mar; 315(9):877-88. PubMed ID: 26906014 [TBL] [Abstract][Full Text] [Related]
16. Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial. Lo J; Lu MT; Ihenachor EJ; Wei J; Looby SE; Fitch KV; Oh J; Zimmerman CO; Hwang J; Abbara S; Plutzky J; Robbins G; Tawakol A; Hoffmann U; Grinspoon SK Lancet HIV; 2015 Feb; 2(2):e52-63. PubMed ID: 26424461 [TBL] [Abstract][Full Text] [Related]
17. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Keech A; Simes RJ; Barter P; Best J; Scott R; Taskinen MR; Forder P; Pillai A; Davis T; Glasziou P; Drury P; Kesäniemi YA; Sullivan D; Hunt D; Colman P; d'Emden M; Whiting M; Ehnholm C; Laakso M; Lancet; 2005 Nov; 366(9500):1849-61. PubMed ID: 16310551 [TBL] [Abstract][Full Text] [Related]
18. Perspectives from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial--Lipid Lowering Trial and the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm. Brown WV; Moussa M Curr Opin Lipidol; 2003 Dec; 14(6):593-7. PubMed ID: 14624136 [TBL] [Abstract][Full Text] [Related]
19. Introducing the 'Drucebo' effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions. Penson PE; Mancini GBJ; Toth PP; Martin SS; Watts GF; Sahebkar A; Mikhailidis DP; Banach M; J Cachexia Sarcopenia Muscle; 2018 Dec; 9(6):1023-1033. PubMed ID: 30311434 [TBL] [Abstract][Full Text] [Related]
20. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. Cholesterol Treatment Trialists' Collaboration Lancet; 2022 Sep; 400(10355):832-845. PubMed ID: 36049498 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]